Skip to main content
. 2023 Apr 18;7:e40028. doi: 10.2196/40028

Table 2.

Characterization of postdischarge persistent symptoms during the second and sixth weeks of follow-up.

Symptoms Week-2 follow-up Week-6 follow-up

Overall (N=120), n (%) Non-ICUa patients (n=70), n (%) ICU patients (n=50), n (%) P
value
Overall (N=120), n (%) Non-ICU patients (n=70), n (%) ICU patients (n=50), n (%) P
value
Fatigue 81 (67.5) 44 (62.9) 37 (74.0) .12 67 (55.8) 38 (54.3) 29 (58.0) .51
Dyspnea 36 (30.0) 17 (24.3) 19 (38.0) .11 24 (20.0) 11 (15.7) 13 (26.0) .17
Anxiety/ depression 10 (8.3) 5 (7.1) 5 (10.0) .58 6 (5.0) 3 (4.3) 3 (6.0) >.99
Fever 2 (1.7) 1 (1.4) 1 (2.0) .99 0 (0) 0 (0) 0 (0) N/Ab
Headache 10 (8.3) 5 (7.1) 5 (10.0) .58 3 (2.5) 1 (1.4) 2 (4.0) .77
Cough 25 (20.8) 10 (14.3) 15 (30.0) .04 12 (10.0) 5 (7.1) 7 (14.0) .22
Myalgia 12 (10.0) 6 (8.6) 6 (12.0) .54 6 (5.0) 3 (4.3) 3 (6.0) >.99
Arthralgia 11 (9.2) 5 (7.1) 6 (12.0) .36 4 (3.3) 2 (2.9) 2 (4.0) >.99
Chest pain 2 (1.7) 1 (1.4) 1 (2.0) .99 1 (0.8) 0 (0) 1 (2.0) .87
Loose stools 11 (9.2) 6 (8.6) 5 (10.0) .79 4 (3.3) 2 (2.9) 2 (4.0) >.99
Loss of appetite 20 (16.7) 9 (12.9) 11 (22.0) .19 13 (10.8) 7 (10.0) 6 (12.0) .73
Weight loss 23 (19.1) 7 (10.0) 16 (32.0) .003 20 (16.7) 13 (18.6) 7 (14.0) .22
Sleep disturbances 21 (17.5) 9 (12.9) 12 (24.0) .11 11 (9.2) 5 (7.1) 6 (12.0) .36
Runny nose 2 (1.7) 1 (1.4) 1 (2.0) .99 0 (0) 0 (0) 0 (0) N/A
Loss of smell 7 (5.8) 4 (5.7) 3 (6.0) >.99 4 (3.3) 2 (2.9) 2 (4.0) >.99
Loss of taste 9 (7.5) 5 (7.1) 4 (8.0) .99 4 (3.3) 2 (2.9) 2 (4%) >.99
Blurred vision 1 (0.8) 1 (1.4) 0 (0) >.99 1 (0.8) 1 (1.4) 0 (0) >.99
Skin rashes 1 (0.8) 0 (0) 1 (2.0) .87 0 (0) 0 (0) 0 (0) N/A
Infections 5 (4.2) 1 (1.4)c 4 (8.0)d .34 2 (1.6) 2 (2.9)e 0 (0) >.99
Oxygen requirement 3 (2.5) 0 (0) 3 (6.0) .14 0 (0) 0 (0) 0 (0) N/A
Hospitalization 7 (5.8) 3 (4.3%) 4 (8.0) .65 4 (3.3) 3 (4.3) 1 (2.0) .86
Able to workf 10 (27.0) 8 (33.3) 2 (15.4) .33 19 (51.4) 13 (54.2) 6 (46.2) .57

aICU: intensive care unit.

bN/A: not applicable.

cGastrointestinal infection.

d2 patients with lower respiratory tract infections and 2 patients with urinary tract infections.

e1 patient with lower respiratory tract infection and 1 patient with gastrointestinal infection.

fPercentages are based on responses from 37 patients who were employed, including 24 at 2-week follow-up and 13 at 6-week follow-up.